NEWSROOM
News & Updates
| 날짜 | 제목 |
|---|---|
2021.01 |  |
2021.01 |  프레스티지바이오파마, 허셉틴 바이오시밀러 중동·북아프리카 시장 라이선스 계약"2021년 1월 19일, 프레스티지바이오파마는 사우디아라비아에 소재한 다국적 제약사 Tabuk Pharmaceuticals (이하 ‘타북’)와 허셉틴 바이오시밀러 ‘HD201’(TUZNUE®)에 대해 사우디아라비아와 아랍에미리트연방을 포함하는 MENA(Middle East and North Africa) 일부 지역 라이선스 계약을 체결했다고 19일 밝혔다. |
2021.01 |  프레스티지바이오파마 "코스피 상장으로 韓바이오 세계화 기여""2021년 1월 18일, 박소연 대표는 “이번 유가증권시장(코스피) 상장을 통해 파이프라인 개발을 가속화하고, 해외 사업 인프라 확장을 통해 한국 바이오사업의 세계화에 기여하겠다.”라고 밝혔다. |
2021.01 | 프레스티지바이오파마 박소연 대표 "바이오시밀러 시장 적극 공략할 무기는 원가 경쟁력""2021년 1월 18일, 프레스티지바이오파마의 박소연 대표이사가 2월 초 코스피 상장을 앞두고 열린 기업설명회에서 "우수한 기술력과 가격경쟁력으로 글로벌 회사로 도약하겠다"라는 포부를 밝혔다. |
2021.01 | Prestige Biopharma to go public in early February"January 18, 2021, Prestige Biopharma, a company specializing in antibody drugs, presented its growth potential and vision as a global biosimilar developer on the occasion of its initial public offering scheduled for next month.출처 : KBR(http://www.koreabiomed.com) |
2021.01 | '올해 첫 바이오 IPO' 프레스티지바이오파마 "글로벌 톱10 항체의약품 제약사 도약""2021년 1월 18일, 새해 첫 바이오 제약 분야 기업공개(IPO) 주자로 나서는 프레스티지바이오파마가 유가증권시장(코스피) 상장을 통해 연 100조원 규모 바이오시밀러 시장과 연 200조 항체신약 시장에서 글로벌 제약사와 본격 경쟁에 나선다. |
2021.01 |  |
2021.01 |  박소연 프레스티지바이오 대표 "가성비 높은 바이오시밀러로 유럽 공략"2021년 1월 10일, 올해 안에 전 세계에 허셉틴 바이오시밀러(바이오의약품 복제약) 판매망을 구축하겠습니다. |
2020.12 |  Near-unicorn Prestige Biopharma eyes early-2021 IPO in South KoreaDecember 12, 2020 Singapore-based Prestige BioPharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021. |
2020.11 |  Prestige Biopharma and Teva Israel Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar (Tuznue™) in IsraelNovember 10, 2020 Prestige BioPharma Ltd. and Abic Marketing Ltd. (operates under the brand of Teva Israel, hereinafter "Teva Israel"), a subsidiary of Teva Pharmaceutical Industries Ltd. announced today that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma's Trastuzumab biosimilar (HD201; Tuznue™) in Israel. |
2020.09 |  Prestige BioPharma Presents Positive Top-Line Results from Phase III and New Data from 3-Arm Phase I Bridging Study for HD201 (Trastuzumab Biosimilar)September 23, 2020 Prestige BioPharma announced positive top-line results from a Phase III global clinical trial have been presented in an oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on September 18, 2020.These top-line results, which confirm no clinically significant differences between HD201 and the originator product Herceptin®, demonstrate HD201’s exceptional similarity to Herceptin® in terms of clinical response and pharmacokinetics (PK), in addition to a comparable safety profile to the range previously observed in other trastuzumab biosimilar clinical trials. Prestige BioPharma also reported that new data from the 3-Arm Phase I Bridging Study have been selected for a poster presentation during the virtual congress on September 17, 2020. The data includes results from a total of 105 healthy male subjects in the 3 arms, in which HD201 demonstrates equivalent PK to both EU-Herceptin® and US-Herceptin®. |
2020.06 |  US FDA Grants Orphan Drug Designation (ODD) for Prestige BioPharma’s PBP1510 Anti-PAUF Monoclonal Antibody for the Treatment of Pancreatic CancerJune 30, 2020 Prestige BioPharma Ltd. (hereinafter “Prestige BioPharma”) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer. |
2019.11 | ![](http://www.prestigebiopharma.com/wp-content/uploads/2019/12/restmb_idxmake.jpeg")  Prestige Biopharma at CPhI Worldwide 2019 in Frankfurt, GermanyNovember 7, 2019 This year's CPhI Worldwide has just concluded and we met with fellow pharmaceutical industry movers and stakeholders. Thank you for visiting Prestige at CPhI Worldwide. |
2019.08 |  Prestige Biopharma partners with Huons to market three key biosimilars in South KoreaAugust 28, 2019 Prestige BioPharma announced that Prestige and Huons have entered into an exclusive partnership for the commercialization of three key biosimilars in South Korea. |
2019.07 |  Prestige Biopharma partners with Mundipharma to market HD201, a trastuzumab biosimilar, in selected European countriesJuly 02, 2019 Prestige BioPharma announced that it has reached a licensing agreement with Mundipharma for its trastuzumab biosimilar (HD201) under which Mundipharma will have exclusive rights to distribute and market the drug in selected European markets. |
2019.06 |  EU Investigator's Meetings for HD204 Bevacizumab Biosimilar Phase III (SAMSON-II ) in Turkey and AustriaJune 26 & 28, 2019 EU Investigator's Meetings for HD204 Bevacizumab Biosimilar Phase III (SAMSON-II ) at Istanbul (Turkey) and Vienna (Austria) were completed successfully! APAC Investigator's Meeting is upcoming. |
2019.06 | Prestige BioPharma Reports Positive Top-Line Phase III Results for Tuznue®June 24, 2019 Prestige BioPharma (herein, Prestige) announced positive top-line results from a Phase III global clinical trial (Troika) evaluating the efficacy, safety, and pharmacokinetics (PK) of biosimilar candidate HD201 to Herceptin (trastuzumab). |
2019.05 |  European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for ReviewMay 28, 2019 Prestige BioPharma (herein, Prestige) announced that European Medicines Agency (EMA) has validated and accepted for review the Marketing Authorization Application (MAA) for its trastuzumab biosimilar HD201 (Tuznue®) on 23 May 2019. |
2019.05 | Successful EMEA Filing Submission for HD201, Herceptin Biosimilar |
2019.03 | Korea FDA GMP Certificate awarded to Prestige Bio Pharmaceuticals (PBK), Prestige's dedicated manufacturing facility |
2019.03 |  2019 Bio Korea : Price Competitiveness is Important in the Biosimilar Market.Michael Kim, Senior Director at Prestige, presented his key insights into winning the biosimilar market. Read it here |
2018.12 |  Prestige Biopharma partners with Cipla Ltd to market key cancer biosimilarDec 14, 2018 Prestige BioPharma announced that it has reached a licensing agreement with Cipla Limited for its trastuzumab biosimilar (HD201) under which Cipla will have exclusive rights to distribute and market the drug in selected emerging markets. |
2018.09 |  Grand Opening of Prestige Bio Pharmaceuticals Korea Osong Campus ISep 13, 2018 PrestigeBio Pharmaceuticals celebrated the successful completion of GMP facility, Osong Campus I, at their grand opening held September 11 in Osong, South Korea. |
2018.07 | Prestige BioPharma Singapore Initiates Listings in Korea Exchange with Samsung SecuritiesJul 11, 2018 Prestige BioPharma and Samsung Securities, Korea (016360) have entered into a sponsorship and underwriting agreement for listing in Korea Exchange. |
2018.06 |  Prestige BioPharma and Alvogen Announce License and Supply AgreementJun 28, 2018 Prestige BioPharma and Alvogen announce License and Supply Agreement: Two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma’s Trastuzumab biosimilar (HD201; Hervelous) in Central and Eastern Europe. |
2018.02 |  Prestige Bio Pharma Introduces Smart Factories Platform in KoreaFeb 21, 2018 Prestige Bio Pharmaceuticals, part of the PrestigeBio Group introduces state-of-the-art process system in collaboration with Thermofisher Scientific in Korea – ‘Smart Factory Platform’. |
Where You Can Find Prestige!
 | Aug 31-Sep 02, 2021 Event: CPhI Worldwide Venue: Milan, Italy | ||
![](http://www.prestigebiopharma.com/kr/wp-content/uploads/2021/01/2021-bio-digital.png") | June 14-17, 2021 Event: BIO 2021 Venue: Online | ||
 | Jan 20-21, 2021 Event: 2021 Global IR Pitching Venue: Online | ||
 | Oct 26-28, 2020 Event: BIO-EUROPE Venue: Virtual | ||
 | Sep 18-17, 2020 Event: ESMO 2020 Venue: Virtual Presentations: Oral & Poster | ||
 | Aug 25-27, 2020 Event: CHINA BIO Venue: Virtual | ||
 | Jun 08-11, 2020 Event: BIO International Convention Venue: Virtual | ||
 | May 29-31, 2020 Event: ASCO 2020 Venue: Virtual Presentation: Poster | ||
 | Nov 5-7, 2019 Event: CPhI Worldwide Venue: Frankfurt, Germany Booth: 120C10 | ||
 | Sep 27- Oct 1, 2019 ESMO 2019 Venue: Barcelona, Spain Booth: 316 | ||
 | May 31- Jun 4, 2019 Event: ASCO 2019 Venue: McCormick Place, Chicago, IL, USA Booth: 5151 | ||
 | Apr 30- May 2, 2019 Event: CPhI North America Venue: McCormick Place, Chicago, IL, USA Booth: 1647 | ||
 | Apr 17 - Apr 19, 2019 Event: BioKorea 2019 Venue: COEX, Seoul, Korea | ||
 | Oct 9-11, 2018 Event: BioLive Europe Venue: IFEMA, Madrid Booth: #12A22 | ||
 | Jan 8- 11, 2018 Event: J.P. Morgan Healthcare Conference Venue: San Francisco, CA | ||
 | Nov 6-8, 2017 Event: Bio-Europe Venue: Berlin, Germany | ||
 | Jun 6 - 9, 2016 Event: Bio International Venue: San Francisco, CA |
브로슈어
파트너십
